From Concept to Cure: The Road Ahead for Ruthenium-Based Anticancer Drugs.

Autor: Swaminathan S; Center for Computational Modelling, Chennai Institute of Technology, Chennai, Tamil Nadu, 600069, India.; Inorganic and Physical Chemistry Laboratory, CSIR-CLRI, Chennai, Tamil Nadu, 600020, India., Haribabu J; Faculty of Medicine, University of Atacama, Los Carreras 1579, Copiapo, 1532502, Chile., Karvembu R; Department of Chemistry, National Institute of Technology, Tiruchirappalli, Tamil Nadu, 620015, India.
Jazyk: angličtina
Zdroj: ChemMedChem [ChemMedChem] 2024 Dec 02; Vol. 19 (23), pp. e202400435. Date of Electronic Publication: 2024 Oct 07.
DOI: 10.1002/cmdc.202400435
Abstrakt: The evolution of chemotherapy, especially the dawn of metal-based drugs, represents a transformative era in cancer treatment. From the serendipitous discovery of mustard gas's cytotoxic effects to the sophisticated development of targeted therapies, chemotherapy has significantly refined. Central to this progression is the incorporation of metal-based compounds, such as platinum (Pt), ruthenium (Ru), and gold (Au), which offer unique mechanisms of action, distinguishing them from organic therapeutics. Among these, Ru complexes, exemplified by BOLD-100 and TLD1433, have shown exceptional promise due to their selective activity, lower propensity for resistance, and the ability to target spescific cellular pathways. This paper explores the journey of such Ru candidates, focusing on the mechanisms, efficacy, and clinical potential of these Ru-based drugs, which stand at the forefront of current research, aiming to provide more targeted, less toxic, and highly effective cancer treatments.
(© 2024 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: